ContraFect Company Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.
Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus.
The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections.
In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients.
Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis.
The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
Contact Details
Address: 28 Wells Avenue Yonkers, Delaware 10701 United States | |
| Phone | 914 207 2300 |
| Website | contrafect.com |
Stock Details
| Ticker Symbol | CFRXQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US2123264093 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Messinger CPA | Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer |
| Natalie Bogdanos J.D. | General Counsel, Corporate Secretary and Data Protection Officer |
| Matthew Salamone P.H.R., SPHR | Vice President of Human Resources |
| Dr. Gary Woodnutt | Senior Vice President of Translational Sciences and Preclinical Development |
| Dr. William Garrett Nichols M.D., M.S. | Interim Chief Medical Officer |